Literature DB >> 31029943

Benzoic acid-derived nitrones: A new class of potential acetylcholinesterase inhibitors and neuroprotective agents.

Catarina Oliveira1, Donatella Bagetta2, Fernando Cagide1, José Teixeira3, Ricardo Amorim3, Tiago Silva3, Jorge Garrido4, Fernando Remião5, Eugenio Uriarte6, Paulo J Oliveira7, Stefano Alcaro2, Francesco Ortuso8, Fernanda Borges9.   

Abstract

The discovery of new chemical entities endowed with potent and selective acetylcholinesterase (AChE) and/or butyrylcholinesterase (BChE) inhibitory activity is still a relevant subject for Alzheimer's disease therapy. Therefore, a small library of benzoic based amide nitrones (compounds 24 to 42) was synthesized and screened toward cholinesterase enzymes. SAR studies showed that the tert-butyl moiety is the most favourable nitrone pattern. In general, tert-butyl derivatives effectively inhibited AChE, being compound 33 the most potent (IC50 = 8.3 ± 0.3 μM; Ki 5.2 μM). The data pointed to a non-competitive inhibition mechanism of action, which was also observed for the standard donepezil. None of compounds showed BChE inhibitory activity. Molecular modelling studies provided insights into the enzyme-inhibitor interactions and rationalised the experimental data, confirming that the binding mode of nitrones 33 and 38 towards AChE has the most favourable binding free energy. The tert-butylnitrones 33 and 38 were not cytotoxic on different cell lines (SH-SY5Y and HepG2). Moreover, compound 33 was able to prevent t-BHP-induced oxidative stress in SH-SY5Y differentiated cells. Due to its AChE selectivity and promising cytoprotective properties, as well as its appropriate drug-like profile pointing toward blood-brain barrier permeability, compound 33 is proposed as a valid lead for a further optimization step.
Copyright © 2019 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  Acetylcholinesterase; Alzheimer's disease; Benzoic acid; Cholinesterase inhibitors; Nitrones; Oxidative stress; Spin traps

Mesh:

Substances:

Year:  2019        PMID: 31029943     DOI: 10.1016/j.ejmech.2019.04.026

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  6 in total

1.  Hydroxybenzoic Acids as Acetylcholinesterase Inhibitors: Calorimetric and Docking Simulation Studies.

Authors:  Grażyna Budryn; Iwona Majak; Joanna Grzelczyk; Dominik Szwajgier; Alejandro Rodríguez-Martínez; Horacio Pérez-Sánchez
Journal:  Nutrients       Date:  2022-06-15       Impact factor: 6.706

2.  Lipid Nanosystems and Serum Protein as Biomimetic Interfaces: Predicting the Biodistribution of a Caffeic Acid-Based Antioxidant.

Authors:  Eduarda Fernandes; Sofia Benfeito; Fernando Cagide; Hugo Gonçalves; Sigrid Bernstorff; Jana B Nieder; M Elisabete Cd Real Oliveira; Fernanda Borges; Marlene Lúcio
Journal:  Nanotechnol Sci Appl       Date:  2021-02-09

3.  Low Molecular Weight (poly)Phenol Metabolites Across the Blood-Brain Barrier: The Underexplored Journey.

Authors:  Rafael Carecho; Diogo Carregosa; Cláudia Nunes Dos Santos
Journal:  Brain Plast       Date:  2021-02-09

4.  A Biophysical Insight of Camptothecin Biodistribution: Towards a Molecular Understanding of Its Pharmacokinetic Issues.

Authors:  Andreia Almeida; Eduarda Fernandes; Bruno Sarmento; Marlene Lúcio
Journal:  Pharmaceutics       Date:  2021-06-12       Impact factor: 6.321

5.  Phenoxyethyl Piperidine/Morpholine Derivatives as PAS and CAS Inhibitors of Cholinesterases: Insights for Future Drug Design.

Authors:  Yaghoub Pourshojaei; Ardavan Abiri; Khalil Eskandari; Zahra Haghighijoo; Najmeh Edraki; Ali Asadipour
Journal:  Sci Rep       Date:  2019-12-27       Impact factor: 4.379

Review 6.  From Hybrids to New Scaffolds: The Latest Medicinal Chemistry Goals in Multi-target Directed Ligands for Alzheimer's Disease.

Authors:  Jazmín Alarcón-Espósito; Michael Mallea; Julio Rodríguez-Lavado
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.